CSTL 250117 12.50P (CSTL250117P12500) Stock Options, News & Quotes

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

CSTL250117P12500

Watchlist

0.45
0.000.00%

15min DelayTrading Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Castle Biosciences to Share Data on DecisionDx-SCC
TipRanksJan 17 07:25 ET
Castle's Poster on DecisionDx-SCC Selected as a "Late Breakers" Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
BusinesswireJan 17 07:00 ET
Insider Sale: Pres. & Chief Exec. Officer of $CSTL (CSTL) Sells 192 Shares
Quiver QuantitativeJan 15 17:01 ET
Castle Biosciences Stock Tumbles Following Guidance Concerns
InvestingJan 13 15:36 ET
Express News | Castle Biosciences Shares Are Trading Lower After the Company Reported Preliminary FY24 Financial Results
BenzingaJan 13 10:24 ET
Castle Biosciences | 8-K: Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
SECJan 13 07:27 ET · Announcements

Comments

Stock_Drift

Oct 20, 2024 04:18

$Castle Biosciences (CSTL.US)$

Teddy123

Sep 29, 2024 21:15

New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients w

$Castle Biosciences (CSTL.US)$
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma | CSTL Stock News

Trytosaveabit

May 29, 2024 15:33

Nice!

$Castle Biosciences (CSTL.US)$ New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis 1 MINUTE AGO, 4:30 PM EDT VIA BUSINESSWIRE

Moomoo AI

Mar 17, 2024 08:44

Despite impressive revenue growth, the high P/S ratio and average growth expectations make the share price seem overvalued. Predicted future revenues may not support this positive sentiment, risking shareholders' investments and potential investors paying a premium.

More Unpleasant Surprises Could Be In Store For Castle Biosciences, Inc.'s (NASDAQ:CSTL) Shares After Tumbling 25%

Moomoo AI

Mar 3, 2024 07:37

Castle Biosciences' progress over the last year is impressive, and it is well-positioned to raise more cash for growth with minimal dilution or borrowing. Its cash burn situation is not risky due to revenue growth and cash burn reduction.

Here's Why We're Not At All Concerned With Castle Biosciences' (NASDAQ:CSTL) Cash Burn Situation